<DOC>
	<DOCNO>NCT01281839</DOCNO>
	<brief_summary>The purpose study investigate effectiveness safety TMC435 compare placebo patient infect genotype 1 hepatitis C virus relapse previous interferon-based therapy . Patients also receive peginterferon alfa-2a ribavirin part treatment .</brief_summary>
	<brief_title>An Efficacy , Safety Tolerability Study TMC435 Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy</brief_title>
	<detailed_description>This randomize , double-blind ( neither physician patient know name assigned drug ) , placebo-controlled study TMC435 patient infect genotype 1 hepatitis C virus relapse previous interferon-based therapy . Patients study also receive two drug infection call peginterferon alfa-2a ribavirin . The purpose study investigate TMC435 superior placebo reduce hepatitis C virus undetectable level 24 week end treatment . For first 12 week , patient take TMC435 placebo , plus peginterferon alfa-2a ribavirin . For next 12 week , patient take peginterferon alfa-2a ribavirin . After , patient continue take peginterferon alfa-2a ribavirin 24 additional week . Other patient stop take peginterferon alfa-2a ribavirin . The study doctor inform patient take study medication stop taking . After patient stop take study medication , continue come doctor 's office study visit total 72 week enroll study . The total duration study 78 week ( include screen ) . Patients monitor safety throughout study . Study assessment study visit may include limited : blood urine collection testing , ECG assessment ( measurement electrical activity heart ) , patient questionnaire , physical examination TMC435 take oral capsule 150 mg per day . Peginterferon ( Pegasys ® ) give injection 180 µg week . Ribavirin ( Copegus ® ) take tablet twice day dose depend body weight .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Genotype 1 hepatitis C infection ( confirmed screening ) Have previously receive peginterferonbased therapy least 24 week document HCV RNA last measurement relapse within 1 year last taking medication Liver biopsy within 3 year screen ( screen baseline visit ) show chronic hepatitis C infection Must agree use 2 form effective contraception throughout study ( male female ) Infection HIV nongenotype 1 hepatitis C Liver disease relate hepatitic C infection Hepatic decompensation Significant laboratory abnormality active disease Pregnant planning become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Hep C</keyword>
	<keyword>Genotype 1</keyword>
</DOC>